Sepracor Reports Preliminary Results from a Second Phase III Study for OMNARIS� HFA Nasal Aerosol in Seasonal Allergic …
Posted on June 30th, 2010 by Content Keyword RSS
MARLBOROUGH, Mass.----Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS� HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis in adult and adolescent patients.
Filed under: Main Content